Kymera Therapeutics (KYMR) | Stock Overview & Key Data
Kymera Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $91.92 on December 28, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics KYMR | 3.01B Mid-cap | 0.39% | -7.10% | 99.05% | 7.06% | 7.14% | 48.07% | 69.92% | 34.67% |
| Vertex VRTX | 114.06B Large-cap | 3.19% | 2.97% | -3.19% | 12.51% | 13.22% | -3.15% | 56.18% | 56.09% |
| Regeneron REGN | 55.27B Large-cap | 2.50% | 3.96% | -6.05% | -26.32% | -24.76% | -47.08% | -11.94% | -11.84% |
| Blueprint Medicines BPMC | 8.29B Mid-cap | 0.17% | 0.34% | 60.10% | 36.06% | 47.25% | 14.91% | 126.85% | 62.53% |
| Roivant Sciences ROIV | 7.82B Mid-cap | -4.70% | -3.07% | 15.98% | -6.77% | -11.09% | 3.19% | 127.07% | 10.79% |
| Bio-Techne TECH | 7.92B Mid-cap | 0.16% | 3.31% | -1.49% | -31.08% | -27.91% | -25.62% | -42.54% | -21.97% |
Ownership & Short Interest
Kymera Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Kymera Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, Kymera Therapeutics reached a high of $53.27 (on September 26, 2024) and a low of $19.44 (on April 9, 2025).
Curious about Kymera Therapeutics's size and valuation? Its market capitalization stands at 3.01B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -14.88.
As for dividends, Kymera Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at Kymera Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX114.06B Healthcare Biotechnology -3.15% 56.18% Regeneron
REGN55.27B Healthcare Biotechnology -47.08% -11.94% Blueprint Medicines
BPMC8.29B Healthcare Biotechnology 14.91% 126.85% Roivant Sciences
ROIV7.82B Healthcare Biotechnology 3.19% 127.07% Bio-Techne
TECH7.92B Healthcare Biotechnology -25.62% -42.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of Kymera Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -32.17%, the Debt to Equity ratio from the most recent quarter is 10.98, and its Gross Profit Margin stands at N/A.
Looking at Kymera Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $59M. Compared to the same quarter last year (YoY), quarterly revenue grew by 114.80%, and quarterly earnings saw a YoY growth of 114.83%.
Wondering who owns Kymera Therapeutics stock? Company insiders (like executives and directors) hold about 2.69% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 111.67%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.